CA2822617A1 - Methods for treating metabolic disorders and obesity with gip and glp-1 receptor-active glucagon-based peptides - Google Patents

Methods for treating metabolic disorders and obesity with gip and glp-1 receptor-active glucagon-based peptides Download PDF

Info

Publication number
CA2822617A1
CA2822617A1 CA2822617A CA2822617A CA2822617A1 CA 2822617 A1 CA2822617 A1 CA 2822617A1 CA 2822617 A CA2822617 A CA 2822617A CA 2822617 A CA2822617 A CA 2822617A CA 2822617 A1 CA2822617 A1 CA 2822617A1
Authority
CA
Canada
Prior art keywords
glp
peptide
extended half
gip
amino acid
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA2822617A
Other languages
English (en)
French (fr)
Inventor
Louis Vignati
Richard D. Dimarchi
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Marcadia Biotech Inc
Original Assignee
Marcadia Biotech Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Marcadia Biotech Inc filed Critical Marcadia Biotech Inc
Publication of CA2822617A1 publication Critical patent/CA2822617A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/26—Glucagons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
    • A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
    • A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A61K9/0021—Intradermal administration, e.g. through microneedle arrays or needleless injectors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Diabetes (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Endocrinology (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Dermatology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Emergency Medicine (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Medicinal Preparation (AREA)
CA2822617A 2010-12-22 2011-12-22 Methods for treating metabolic disorders and obesity with gip and glp-1 receptor-active glucagon-based peptides Abandoned CA2822617A1 (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201061426338P 2010-12-22 2010-12-22
US61/426,338 2010-12-22
US201161500229P 2011-06-23 2011-06-23
US61/500,229 2011-06-23
PCT/US2011/066739 WO2012088379A2 (en) 2010-12-22 2011-12-22 Methods for treating metabolic disorders and obesity with gip and glp-1 receptor-active glucagon-based peptides

Publications (1)

Publication Number Publication Date
CA2822617A1 true CA2822617A1 (en) 2012-06-28

Family

ID=46314922

Family Applications (1)

Application Number Title Priority Date Filing Date
CA2822617A Abandoned CA2822617A1 (en) 2010-12-22 2011-12-22 Methods for treating metabolic disorders and obesity with gip and glp-1 receptor-active glucagon-based peptides

Country Status (14)

Country Link
US (2) US8975223B2 (https=)
EP (1) EP2654774A4 (https=)
JP (1) JP2014501762A (https=)
KR (1) KR20140020851A (https=)
CN (1) CN103402536A (https=)
AR (1) AR084558A1 (https=)
AU (1) AU2011348202A1 (https=)
BR (1) BR112013015861A2 (https=)
CA (1) CA2822617A1 (https=)
MX (1) MX2013007327A (https=)
NZ (1) NZ611878A (https=)
RU (1) RU2013133803A (https=)
SG (1) SG191252A1 (https=)
WO (1) WO2012088379A2 (https=)

Families Citing this family (70)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2528618A4 (en) * 2010-01-27 2015-05-27 Univ Indiana Res & Tech Corp GLUCAGON ANTAGONISTE AND GIP AGONISTS CONJUGATES AND COMPOSITIONS FOR THE TREATMENT OF METABOLISM DISEASES AND ADIPOSITAS
PE20240686A1 (es) 2011-06-10 2024-04-10 Hanmi Science Co Ltd Peptidos derivados de oxintomodulina con actividad sobre el receptor de glucagon y el receptor de peptido similar a glucagon de tipo 1 (glp-1)
PE20230404A1 (es) 2011-06-17 2023-03-07 Hanmi Science Co Ltd Un conjugado que comprende oxintomodulina y un fragmento de inmunoglobulina, y uso del mismo
WO2013006486A2 (en) 2011-07-01 2013-01-10 Ngm Biopharmaceuticals, Inc. Compositions, uses and methods for treatment of metabolic disorders and diseases
RU2610175C2 (ru) 2011-09-23 2017-02-08 Ново Нордиск А/С Новые аналоги глюкагона
KR101968344B1 (ko) 2012-07-25 2019-04-12 한미약품 주식회사 옥신토모듈린 유도체를 포함하는 고지혈증 치료용 조성물
KR101993393B1 (ko) 2012-11-06 2019-10-01 한미약품 주식회사 옥신토모듈린 유도체를 포함하는 당뇨병 또는 비만성 당뇨병 치료용 조성물
PE20151421A1 (es) 2012-11-06 2015-09-24 Hanmi Pharm Ind Co Ltd Formulacion liquida del conjugado de proteina que comprende la oxintomodulina y un fragmento de inmunoglobulina
US9290557B2 (en) 2012-11-28 2016-03-22 Ngm Biopharmaceuticals, Inc. Compositions comprising variants and fusions of FGF19 polypeptides
HK1214832A1 (zh) 2012-11-28 2016-08-05 恩格姆生物制药公司 用於代謝病症和疾病治療的組合物和方法
US9273107B2 (en) 2012-12-27 2016-03-01 Ngm Biopharmaceuticals, Inc. Uses and methods for modulating bile acid homeostasis and treatment of bile acid disorders and diseases
MX383664B (es) 2012-12-27 2025-03-14 Ngm Biopharmaceuticals Inc Uso de un péptido para modular la homeostasis de los ácidos biliares o tratamiento de una enfermedad relacionada con los ácidos biliares.
SI2986313T1 (sl) * 2013-04-18 2019-09-30 Novo Nordisk A/S Stabilni koagonisti GLP-1 / glukagonskega receptorja z dolgotrajnim učinkom za medicinsko uporabo
LT3004155T (lt) * 2013-05-28 2021-12-27 Takeda Pharmaceutical Company Limited Peptidų junginys
WO2015035419A1 (en) * 2013-09-09 2015-03-12 Hoffmann-La Roche Inc. Dosages of gip/glp-1 co-agonist peptides for human administration
CN105792851B (zh) * 2013-09-13 2023-10-10 斯克利普斯研究所 修饰的治疗剂及其组合物
WO2015065897A1 (en) 2013-10-28 2015-05-07 Ngm Biopharmaceuticals, Inc. Cancer models and associated methods
CN112043835B (zh) 2013-12-06 2022-10-21 韩捷 用于含氮和羟基的药物的生物可逆引入基团
AU2014364589B2 (en) 2013-12-18 2020-02-27 The California Institute For Biomedical Research Modified therapeutic agents, stapled peptide lipid conjugates, and compositions thereof
AR098616A1 (es) 2013-12-18 2016-06-01 Lilly Co Eli Péptido para el tratamiento de hipoglicemia severa
PT3097122T (pt) 2014-01-24 2020-07-21 Ngm Biopharmaceuticals Inc Anticorpos de ligação de domínio 2 de beta klotho e métodos de utilização dos mesmos
TW201625669A (zh) * 2014-04-07 2016-07-16 賽諾菲公司 衍生自艾塞那肽－４（Ｅｘｅｎｄｉｎ－４）之肽類雙重ＧＬＰ－１／升糖素受體促效劑
US10398758B2 (en) 2014-05-28 2019-09-03 Ngm Biopharmaceuticals, Inc. Compositions comprising variants of FGF19 polypeptides and uses thereof for the treatment of hyperglycemic conditions
US10570184B2 (en) 2014-06-04 2020-02-25 Novo Nordisk A/S GLP-1/glucagon receptor co-agonists for medical use
WO2015195509A2 (en) 2014-06-16 2015-12-23 Ngm Biopharmaceuticals, Inc. Methods and uses for modulating bile acid homeostasis and treatment of bile acid disorders and diseases
CA2952905A1 (en) * 2014-08-06 2016-02-11 Nestec S.A. Biomarkers for predicting degree of weight loss
US10968266B2 (en) 2014-09-05 2021-04-06 University Of Copenhagen GIP peptide analogues
TWI802396B (zh) * 2014-09-16 2023-05-11 南韓商韓美藥品股份有限公司 長效glp-1/高血糖素受體雙促效劑治療非酒精性脂肝疾病之用途
CN114129709A (zh) 2014-10-23 2022-03-04 恩格姆生物制药公司 包含肽变异体的药物组合物及其使用方法
CR20170164A (es) 2014-10-24 2017-08-29 Merck Sharp & Dohme Coagonistas de los receptores de glucagón y de glp-1
US10434144B2 (en) 2014-11-07 2019-10-08 Ngm Biopharmaceuticals, Inc. Methods for treatment of bile acid-related disorders and prediction of clinical sensitivity to treatment of bile acid-related disorders
JP2018012644A (ja) * 2014-11-26 2018-01-25 武田薬品工業株式会社 ペプチド化合物
KR102418477B1 (ko) 2014-12-30 2022-07-08 한미약품 주식회사 글루카곤 유도체
JO3575B1 (ar) * 2015-01-09 2020-07-05 Lilly Co Eli مركبات مساعد مشترك من gip وglp-1
KR101669140B1 (ko) 2015-04-28 2016-10-26 (주)케어젠 항비만 및 항당뇨 효능을 갖는 펩타이드 및 이의 용도
WO2017019957A2 (en) 2015-07-29 2017-02-02 Ngm Biopharmaceuticals, Inc. Binding proteins and methods of use thereof
TWI622596B (zh) 2015-10-26 2018-05-01 美國禮來大藥廠 升糖素受體促效劑
JP6728352B2 (ja) 2015-11-09 2020-07-22 エヌジーエム バイオファーマシューティカルス，インコーポレーテッド 胆汁酸に関係した障害の治療方法
AR107890A1 (es) * 2016-03-10 2018-06-28 Medimmune Ltd Co-agonistas de glucagón y de glp-1 para el tratamiento de la obesidad
WO2017204219A1 (ja) 2016-05-24 2017-11-30 武田薬品工業株式会社 ペプチド化合物
EP3503882A4 (en) 2016-08-26 2020-07-29 NGM Biopharmaceuticals, Inc. METHOD FOR TREATING FIBROBLAST GROWTH FACTOR-19-MEDIATED CARCINOMAS AND TUMORS
CN109200273B (zh) * 2017-07-04 2021-02-19 中国药科大学 一种多肽用于制备预防或治疗脂肪肝病药物的用途
JOP20190211A1 (ar) 2017-03-31 2019-09-15 Takeda Pharmaceuticals Co ببتيد منشط لمستقبل gip
PL3630806T3 (pl) * 2017-05-31 2024-05-13 The University Of Copenhagen Analogi peptydów gip o długotrwałym działaniu
US10470311B2 (en) * 2017-09-28 2019-11-05 Juniper Networks, Inc. Clearance size reduction for backdrilled differential vias
JP7148605B2 (ja) 2017-10-12 2022-10-05 ノヴォ ノルディスク アー／エス 医学療法におけるセマグルチド
KR102379958B1 (ko) * 2018-05-04 2022-04-01 노보 노르디스크 에이/에스 Gip 유도체 및 이의 용도
CN120754229A (zh) * 2018-07-23 2025-10-10 伊莱利利公司 使用gip/glp1共激动剂用于治疗的方法
CN121449721A (zh) 2018-12-03 2026-02-03 安泰博医药 经修饰的gip肽类似物
CN109379770B (zh) * 2018-12-11 2021-04-06 北京百瑞互联技术有限公司 蓝牙mesh网络的路径辅助候选节点的优选方法、装置及节点
AU2020206388B2 (en) * 2019-01-07 2022-12-01 Vitalixir (Beijing) Co., Ltd Novel polypeptide and therapeutic uses thereof
WO2021083306A1 (zh) * 2019-10-31 2021-05-06 东莞市东阳光生物药研发有限公司 Glp-1/gcg双受体激动剂多肽
AU2020397917A1 (en) 2019-12-04 2022-06-23 The Scripps Research Institute GLP2 receptor agonists and methods of use
WO2021169512A1 (zh) * 2020-02-24 2021-09-02 中山大学 多肽化合物及其在预防或治疗糖尿病或糖尿病并发症中的应用
CN116113429A (zh) * 2020-07-06 2023-05-12 鸿绪生物医药科技（北京）有限公司 新型多肽及其治疗用途
MX2023000303A (es) * 2020-07-22 2023-02-09 Novo Nordisk As Coagonistas de los receptores del peptido 1 similar al glucagon (glp-1) y del polipeptido insulinotropico dependiente de glucosa (gip) adecuados para el suministro oral.
BR112023000229A2 (pt) * 2020-07-22 2023-01-31 Novo Nordisk As Composto, composição farmacêutica, e, peptídeo
MX2023001599A (es) * 2020-08-14 2023-03-07 Hanmi Pharmaceutical Co Ltd Composicion farmaceutica que comprende un conjugado de accion prolongada del triple agonista del receptor de glucagon/glp-1/gip.
WO2022080986A1 (ko) * 2020-10-16 2022-04-21 한미약품 주식회사 Glp-1/gip 이중작용제, 이의 지속형 결합체, 및 이를 포함하는 약학적 조성물
EP4257597A4 (en) * 2020-12-02 2025-04-02 Dongbao Purple Star (Hangzhou) Biopharmaceutical Co., Ltd. LACTAM-MODIFIED POLYPEPTIDE COMPOUNDS
CN114891071A (zh) * 2020-12-08 2022-08-12 鸿绪生物科技(嘉善)有限公司 新型多肽及其治疗用途
CN114617956B (zh) * 2020-12-10 2023-10-03 江苏中新医药有限公司 一种高效降糖的蛋白质药物
IL308392A (en) 2021-05-13 2024-01-01 Carmot Therapeutics Inc G protein-coupled receptor modulators
MX2023014771A (es) * 2021-06-09 2024-03-19 Scripps Research Inst Conjugados peptidicos duales gip/glp-1 de accion prolongada y metodos de uso.
CA3237796A1 (en) * 2021-11-12 2023-05-19 Zhenbin Li Pharmaceutical composition of glp-1 receptor and gip receptor dual agonist, and use thereof
TW202330584A (zh) 2022-01-20 2023-08-01 丹麥商諾佛 儂迪克股份有限公司 前藥及其用途
CN116143884B (zh) * 2023-02-03 2023-08-04 江苏师范大学 一类长效GLP-1/glucagon/GIP受体三重激动剂及其应用
KR20260005268A (ko) * 2023-04-23 2026-01-09 카모트 테라퓨틱스 인크. 당뇨병 치료
WO2026046202A1 (zh) * 2024-08-26 2026-03-05 博瑞生物医药（苏州）股份有限公司 Glp-1/gip肽或含有其的药物组合物的用途
WO2026046328A1 (en) * 2024-08-30 2026-03-05 Beijing Ql Biopharmaceutical Co., Ltd. Dosing regimen of glp-1 conjugates

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7846445B2 (en) 2005-09-27 2010-12-07 Amunix Operating, Inc. Methods for production of unstructured recombinant polymers and uses thereof
US8933197B2 (en) 2007-08-15 2015-01-13 Amunix Operating Inc. Compositions comprising modified biologically active polypeptides
AU2009210570B2 (en) 2008-01-30 2014-11-20 Indiana University Research And Technology Corporation Ester-based insulin prodrugs
DK2300035T3 (en) * 2008-06-17 2015-11-16 Univ Indiana Res & Tech Corp Mixed GIP-based agonists for the treatment of metabolic diseases and obesity
CN102325539A (zh) 2008-12-19 2012-01-18 印第安纳大学研究及科技有限公司 基于酰胺的胰高血糖素超家族肽前药
WO2010148089A1 (en) 2009-06-16 2010-12-23 Indiana University Research And Technology Corporation Gip receptor-active glucagon compounds
EP2528618A4 (en) 2010-01-27 2015-05-27 Univ Indiana Res & Tech Corp GLUCAGON ANTAGONISTE AND GIP AGONISTS CONJUGATES AND COMPOSITIONS FOR THE TREATMENT OF METABOLISM DISEASES AND ADIPOSITAS
US8507428B2 (en) 2010-12-22 2013-08-13 Indiana University Research And Technology Corporation Glucagon analogs exhibiting GIP receptor activity

Also Published As

Publication number Publication date
NZ611878A (en) 2015-02-27
RU2013133803A (ru) 2015-01-27
WO2012088379A2 (en) 2012-06-28
KR20140020851A (ko) 2014-02-19
SG191252A1 (en) 2013-07-31
CN103402536A (zh) 2013-11-20
AU2011348202A1 (en) 2013-07-04
US20140018291A1 (en) 2014-01-16
WO2012088379A9 (en) 2012-11-08
BR112013015861A2 (pt) 2018-06-05
AR084558A1 (es) 2013-05-22
MX2013007327A (es) 2014-01-08
US20160175400A1 (en) 2016-06-23
JP2014501762A (ja) 2014-01-23
AU2011348202A9 (en) 2016-03-24
US8975223B2 (en) 2015-03-10
EP2654774A2 (en) 2013-10-30
EP2654774A4 (en) 2015-07-01

Similar Documents

Publication Publication Date Title
US8975223B2 (en) Methods for treating metabolic disorders and obesity with a peptide comprising the amino acid sequence of SEQ ID No. 146
JP7461997B2 (ja) 制御放出および持続的放出のためのｅｌｐ融合タンパク質
KR102161177B1 (ko) 지속형 인슐린분비 펩타이드 결합체 액상 제제
AU2010257216B2 (en) GLP-1 and methods for treating diabetes
AU2003208945B2 (en) Method for administering GLP-1 molecules
JP6755175B2 (ja) インスリン投薬レジメン
WO2021136302A1 (zh) 胰岛素衍生物
MX2011004357A (es) Tratamiento de diabetes mellitus utilizando inyecciones de insulina con una frecuencia de inyeccion menor que a diario.
JP2008504249A (ja) 糖尿病を治療するための方法
TW201113032A (en) Slow-acting insulin preparations
SG174770A1 (en) Methods for administering long-lasting hypoglycemic agents
EP3295952A1 (en) Pharmaceutical formulation comprising glp-1 analogue and preparation method thereof
US20260053895A1 (en) Pharmaceutical compositions and their uses, and methods for improving the storage stability of pharmaceutical compositions
EP4371577A1 (en) Composition for orally administered formulation containing glp-1 analogue
WO2015035419A1 (en) Dosages of gip/glp-1 co-agonist peptides for human administration
HK1191551A (en) Methods for treating metabolic disorders and obesity with gip and glp-1 receptor-active glucagon-based peptides
TW201238972A (en) Methods for treating metabolic disorders and obesity with GIP and GLP-1 receptor-active glucagon-based peptides
HK40070502B (zh) 胰岛素衍生物
HK1075456B (en) Glp-1 and methods for treating diabetes

Legal Events

Date Code Title Description
FZDE Dead

Effective date: 20171222